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0% CABG, 0% reintervention, 2% rehospitalization for
CHF, 1.4% rehospitalization for ACS.
Conclusion: CTO requires endless patience from the
cardiologist. There is no need to abuse the resources of
the cath lab if we follow the protocol of TO BELIEVERS.
Excellent results can be obtained if CTO intervention
done by using these basic equipments.
http://dx.doi:10.1016/j.jsha.2013.03.170
Statin and ezetimibe in silent ambulatory myocar-
dial ischemia (sesami trial)
Waleed Y. Kadro, Maya Turkmani, Hussam
Rahim, Owais Altisheh, Ali Debs
Background: Cholesterol lowering is associated with
a reduction in cardiovascular morbidity and mortality.
Statins are the main drugs for cholesterol lowering. Eze-
timibe when added to statins gives further reduction in
cholesterol but its long-term effect on cardiovascular
morbidity and mortality and ischemic events is not
known. This study sought to determine whether further
cholesterol lowering with ezitimibe will also results in a
reduction of myocardial ischemia during daily life.
Methods: We enrolled 50 patients with proven stable
coronary artery disease (CAD) and at least one episode of
ST-segment depression on ambulatory ECG monitoring.
All of them were receiving optimal therapy for CAD
including statin therapy for cholesterol reduction. 25
patients were randomized to continue their statin ther-
apy (Statin only group) and 25 to recieve statin plus ezi-
timibe 10 mg/day (ezitimibe group). Serum cholesterol
and LDL cholesterol levels and ambulatory monitoring
were repeated after 4–6 months of therapy. The two
groups were comparable with respect to baseline charac-
teristics, number of episodes of ST-segment depression,
and baseline serum cholesterol levels. Holters were read
by a blinded cardiologist.
Results: The ezitimibe group had lower mean total
and LDL cholesterol levels at study end and experienced
a significant reduction in the number of episodes of ST-
segment depression compared with the statin only
group. ST-segment depression was completely resolved
in 13 of 25 patients (52%) in the ezitimibe group versus
3 of 25 (12%) in the statin only group. The ezitimibe group
exhibited a highly significant reduction in ambulatory
ischemia (P < .001). By logistic regression, treatment with
ezitimibe was an independent predictor of ischemia
resolution.
Conclusions: Further cholesterol lowering with ezi-
timibe can result in reduction or resolution of myocardial
ischemia recorded as episodes of ST-segment depression
in ambulatory monitoring of the ECG.
http://dx.doi:10.1016/j.jsha.2013.03.171
Troponin level before coronary artery bypass graft
surgery is associated with increased mortality rate
Walid Abukhudair, Massimo Porqueddo,
Nazir Ahmed, Ahmed Hafed, Abdullah Ashmeg,
Thamer Bin Yousef
Objective: Cardiac troponin level indicate extend of
miocardial injury.
Coronary artery bypass graft surgery early post myo-
cardial infartion is associated with high mortality, trying
to find a quantitative piameter to determine the high risk
patients.
Method: Prospective data collection of troponin level
and outcome of coronary artery bypass graft surgery was
collected over 3 years (30 days mortality).
Result: A total of 550 patients who had CABG over
3 years was collected, the patients were divided into 3
groups. Group 1 patient with troponin less than 3. Group
2 patient with troponin between 3 and 5. Group 3 patient
with troponin above 5. The 30 days mortality was propor-
tionally correlated to the troponin level. Group 1 had a
mean mortality of less than 2%, group 2 had a mean mor-
tality of 3.5%, and group 3 had a mean mortality rate of
10%.
Conclusion: Preoperative 30 days mortality post
CABG is proportionally related to the extend of myocar-
dial damage which is reflected by trop in level. When
possible it is better to wait and delay surgery until tropo-
nin level below 3.
http://dx.doi:10.1016/j.jsha.2013.03.172
Proper method for preoperative chest preparation
of patients listed for cardiac surgery
Walid Abdulkarim Abukhudair
Context: Postoperative pulmonary complication
(PCCs) after cardiac surgery are a major source of mor-
bidity and mortality, and increase length of hospital stay
and resource utilization. The preoperative including pre-
hospitlization period before CARDIAC surgery maybe
used to improve a patients pulmonary condition. The
efficacy of preoperative non-invasive CPAP and BIPAP
machine use, chest physiotherapy (CPT) and postural
drainage, frequent nebulization plus inspiratory muscle
training (IMT) in reducing the incidence of PPCs in
high-risk patients undergoing CARDIAC surgery has
not yet been determined.
Objective: To evaluate the prophylactic efficacy of
our new preoperative chest preparation strategy (strategy
A) on the incidence of PPCs in high risk patients sched-
uled for elective CARDIAC surgery compared with clas-
sic routinely used one (Strategy B).
Design, setting, and patients: A single blind,
randomized clinical trial conducted at the Cardiac
Center of Kind Fahad Armed forces Hospital, Jeddah,
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Saudi Arabia, with the enrollment between November
2011 and October 2012. Of 500 patients referred for
elective CARDIAC surgery, 100 (20%) met criteria for
high risk of developing PPCs, of whom were enrolled
and followed up until discharge from hospital after
dividing him to two groups, our new preoperative chest
preparation strategy group (group A) and classic
routinely used group (group B).
Intervention: Patients were randomly assigned to
receive either preoperative strategy (n = 50) or usual care
B strategy (n = 50). Both groups received the postopera-
tive physical therapy.
Main outcome measures: Incidence of PPCs espe-
cially pneumonia, duration of postoperative intubation
and invasive ventilation, Intensive Care Unit (ICU) stay
and hospitalization incidence of requiring re-intubation
and impact of both strategies on postoperative patient
compliance to respiratory therapy.
Results: Both groups were comparable at baseline.
After CARDIAC surgery, PPCs were present in 10
(20%) of patients in the A group and 25 (50%) of patients
B group. Pneumonia occurred in 5 (10%) of patients in the
A group and in 7 (14%) of patients in the B (OR 95% CI).
Median days range 6–18 days in the B group. Finally,
postoperative patients compliance to respiratory therapy
was significantly improved.
Conclusion: Preoperative A strategy reduced the
incidence of PPCs an duration of postoperative hospital-
ization in patients at high risk of developing pulmonary
complication undergoing CARDIAC surgery. Also, post-
operative patient compliance to respirartory therapy
was significantly improved.
http://dx.doi:10.1016/j.jsha.2013.03.175
Current outcomes of the Glenn bidirectional cavo-
pulmonary connection for single ventricle
palliation
Waheed Raedi, Majid Al Fayyadh, Momdouh Al
Ahmadi, Bahaa Alsoufi
Objectives: The Glenn bidirectional cavopulmonary
connection (BCPC) is an established procedure in multi-
stage palliation of various single ventricle anomalies. We
aimed to report current outcomes following BCPC and to
examine risk factors affecting survival and progression to
next palliation stage.
Methods: 227 consecutive children with variable sin-
gle ventricle pathologies underwent BCPC from 2002 to
2007. Competing risks analyses were performed to model
events after BCPC (death and transition to Fontan) and
subsequently after Fontan (death and cardiac reopera-
tion); and to examine associated risk factors for poor
outcomes.
Results: There were 139 males (61%) with median age
of 7.6 months (interquartile range (IQR) 6.0–10.8) and med-
ian weight of 6.2 kg (IQR 5.2–7.4). Forty-three patients (19%)
had primary BCPC and 184 (81%) had prior palliation: aor-
topulmonary shunt (n = 83), Norwood (n = 55), pulmonary
artery band (n = 48), atrial septectomy (n = 25), pulmonary
artery reconstruction (n = 14), anomalous pulmonary
venous connection repair (n = 7), other (n = 8). Predomi-
nant ventricle was left morphology (n = 122, 54%), right
morphology (n = 95, 42%), two equally developed ventri-
cles (n = 10, 4%). Twenty-six patients (12%) had bilateral
SVC. Concomitant surgery included atrioventricular valve
repair (n = 18), pulmonary artery augmentation (n = 80),
percutaneous Fontan preparation (n = 34), other (n = 24).
Competing risks analysis showed that 5-years following
BCPC, approximately 17% have died, 76% have undergone
Fontan and 7% were alive awaiting or not qualifying for
Fontan. On multivariable analysis, risk factors for death
prior to Fontan were PVRI > 3 WU/M2 (HR 3.9, p = 0.001),
dominant right ventricle (HR 2.1, p = 0.03), prior palliation
other than aortopulmonary shunt (HR 0.4, p = 0.03). Com-
peting risks analysis showed that 3-years following 172
Fontan operations, approximately 10% have died, 6% have
undergone further cardiac surgery and 84% were alive and
free from reoperation. Overall, 8-year survival following
BCPC was only 74%.
Conclusions: Despite established selection criteria
and improved surgical technique and medical manage-
ment, there is a continuous failure and attrition risk fol-
lowing BCPC. Outcomes are influenced by underlying
cardiac anomaly; patients with dominant left ventricle
(i.e. tricuspid atresia, DILV) having the best survival
while those with dominant right ventricle (i.e. HLHS,
DORV with heterotaxy) having the worst survival.
Increased pulmonary vascular resistance remains a sig-
nificant factor affecting mortality.
http://dx.doi:10.1016/j.jsha.2013.03.176
Role of biomarkers to identify individuals with
silent cardiac disease to help improve primary
prevention
Yahia M. Elrakshy a, Akram M. Fayed b
aCardiology Department, Alexandria University Hospi-
tal, Egypt; bCritical Care Department, Faculty of Med-
icine, Alexandria, Egypt
Objectives: The aim of this study was to evaluate
power of identification of silent cardiac target organ dam-
age (TOD) in population receiving primary prevention
with the use of biomarkers.
Background: Primary prevention of cardiovascular
events could be improved by identifying patients with
silent cardiac TOD (i.e., myocardial ischemia, systolic
dysfunction, diastolic dysfunction, left ventricular hyper-
trophy or left atrial enlargement). Biomarkers used for
screening included high sensitive CRP [hs-CRP], high
sensitivity cardiac troponin T [hs-cTnT], or B-type natri-
uretic peptide [BNP].
Methods: The study included 271 asymptomatic
individuals already receiving primary prevention
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